

# Vassilios Papademetriou

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3775610/vassilios-papademetriou-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

239  
papers

10,682  
citations

53  
h-index

98  
g-index

260  
ext. papers

12,078  
ext. citations

5.2  
avg, IF

5.63  
L-index

#	Paper	IF	Citations
239	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium.. <i>Circulation</i> , <b>2022</b> , 145, 847-863	16.7	3
238	The Impact of Various Blood Pressure Measurements on Cardiovascular Outcomes. <i>Current Vascular Pharmacology</i> , <b>2021</b> , 19, 313-322	3.3	0
237	Effect of Intensive Versus Standard Blood Pressure Control on Stroke Subtypes. <i>Hypertension</i> , <b>2021</b> , 77, 1391-1398	8.5	0
236	Joint ESH excellence centers National meeting on renal sympathetic denervation: A Greek experts survey. <i>Hellenic Journal of Cardiology</i> , <b>2021</b> , 62, 355-358	2.1	1
235	Hypertension in Pregnancy: Unanswered Questions. <i>Current Pharmaceutical Design</i> , <b>2021</b> , 27, 3795-3803	3.3	0
234	Response by Latif et al to Letter Regarding Article, "Stent-Only Versus Adjunctive Balloon Angioplasty Approach for Saphenous Vein Graft Percutaneous Coronary Intervention: Insights From DIVA Trial". <i>Circulation: Cardiovascular Interventions</i> , <b>2020</b> , 13, e009174	6	
233	Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and meta-analysis of randomized, sham-controlled, catheter-based trials. <i>Journal of Clinical Hypertension</i> , <b>2020</b> , 22, 572-584	2.3	17
232	Pharmacological Management of Diabetic Nephropathy. <i>Current Vascular Pharmacology</i> , <b>2020</b> , 18, 139-147	3.3	1
231	Left Ventricular Hypertrophy and Mortality Risk in Male Veteran Patients at High Cardiovascular Risk. <i>American Journal of Cardiology</i> , <b>2020</b> , 125, 887-893	3	2
230	Effects of Intensive Blood Pressure Control in Patients with and without Albuminuria: Analyses from SPRINT. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2020</b> , 15, 1121-1128	6.9	5
229	Primary Aldosteronism: Novel Insights. <i>Current Hypertension Reviews</i> , <b>2020</b> , 16, 19-23	2.3	3
228	Mild to moderate chronic kidney disease and cardiovascular events in patients with type 2 diabetes mellitus. <i>Vascular Health and Risk Management</i> , <b>2019</b> , 15, 365-373	4.4	6
227	Orthostatic hypotension: From pathophysiology to clinical applications and therapeutic considerations. <i>Journal of Clinical Hypertension</i> , <b>2019</b> , 21, 546-554	2.3	24
226	Now That Renal Denervation Works, How Do We Proceed?. <i>Circulation Research</i> , <b>2019</b> , 124, 693-695	15.7	11
225	Insomnia and hypertension: A misty landscape. <i>Journal of Clinical Hypertension</i> , <b>2019</b> , 21, 835-837	2.3	2
224	Morning Surge and Peak Morning Ambulatory Blood Pressure Versus Automated Office Blood Pressure in Predicting Cardiovascular Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2019</b> , 26, 209-215	2.9	8
223	Attended Versus Unattended Automated Office Blood Pressure: A Systematic Review and Meta-analysis. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2019</b> , 26, 293-303	2.9	7

222	Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2019</b> , 30, 1523-1533	12.7	24
221	Effect of Intensive Blood Pressure Reduction on Left Ventricular Mass, Structure, Function, and Fibrosis in the SPRINT-HEART. <i>Hypertension</i> , <b>2019</b> , HYPERTENSIONAHA11913073	8.5	15
220	New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. <i>International Journal of Cardiology: Hypertension</i> , <b>2019</b> , 3, 100022	1.6	
219	Determinants of pulse wave velocity index and potential implementations. <i>Journal of Clinical Hypertension</i> , <b>2019</b> , 21, 1493-1495	2.3	1
218	Inhibition of the renin-angiotensin system in the cardiorenal syndrome with anaemia: a double-edged sword. <i>Journal of Hypertension</i> , <b>2019</b> , 37, 2145-2153	1.9	3
217	The VA Co-operative Studies; The First RCTs in Cardiovascular Disease [A Tribute to Edward D. Freis <b>2019</b> , 75-88		
216	Hypertension Management in African Americans: The AASK and Other Landmark Trial Application <b>2019</b> , 145-154		
215	The clinical value of automated office blood pressure: What is the latest evidence on attended vs unattended automated readings in clinical practice?. <i>Journal of Clinical Hypertension</i> , <b>2019</b> , 21, 156-158	2.3	1
214	Attended and Unattended Automated Office Blood Pressure Measurements Have Better Agreement With Ambulatory Monitoring Than Conventional Office Readings. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	28
213	Cardiovascular morbidity of severe resistant hypertension among treated uncontrolled hypertensives: a 4-year follow-up study. <i>Journal of Human Hypertension</i> , <b>2018</b> , 32, 487-493	2.6	5
212	A case of influenza type a myocarditis that presents with ST elevation MI, cardiogenic shock, acute renal failure, and rhabdomyolysis and with rapid recovery after treatment with oseltamivir and intra-aortic balloon pump support. <i>Cardiovascular Revascularization Medicine</i> , <b>2018</b> , 19, 37-42	1.6	4
211	Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control. <i>Circulation</i> , <b>2018</b> , 137, 134-143	16.7	89
210	The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 5517-5524	3.3	3
209	Place of Invasive Procedures in Blood Pressure Control. <i>Updates in Hypertension and Cardiovascular Protection</i> , <b>2018</b> , 853-865	0.1	
208	PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2018</b> , 13, 1816-1824	6.9	10
207	Serial changes in vessel walls of renal arteries after catheter-based renal artery denervation: insights from volumetric computed tomography analysis. <i>International Journal of Nephrology and Renovascular Disease</i> , <b>2018</b> , 11, 259-266	2.5	0
206	Unobserved automated office BP is similar to other clinic BP measurements: A prospective randomized study. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 1411-1416	2.3	11
205	Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2018</b> , 13, 1693-1702	6.9	15

204	Prognostic relevance of visit-to-visit office blood pressure variability in Systolic Blood Pressure Intervention Trial: Same data, different conclusions?. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 1644-1645 <sup>2,3</sup>	2
203	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. <i>Lancet, The</i> , <b>2018</b> , 391, 2346-2355	40 358
202	The Role of Angiogenesis Inhibitors in Hypertension: Following "Ariadne's Thread". <i>American Journal of Hypertension</i> , <b>2018</b> , 31, 961-969	2.3 4
201	The Reply. <i>American Journal of Medicine</i> , <b>2018</b> , 131, e317	2.4 0
200	Effect of Intensive Blood Pressure Control on Gait Speed and Mobility Limitation in Adults 75 Years or Older: A Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , <b>2017</b> , 177, 500-507	11.5 28
199	Systolic-diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the Cardiovascular Health Study. <i>International Journal of Cardiology</i> , <b>2017</b> , 235, 11-16	3.2 21
198	Olmесartan worsening known thrombocytopenia. A rare side effect of antihypertensive drugs. <i>Hellenic Journal of Cardiology</i> , <b>2017</b> , 58, 96-97	2.1 1
197	Home, automated office, and conventional office blood pressure as predictors of cardiovascular risk. <i>Journal of the American Society of Hypertension</i> , <b>2017</b> , 11, 165-170.e2	14
196	Effects of multielectrode renal denervation on elevated sympathetic nerve activity and insulin resistance in metabolic syndrome. <i>Journal of Hypertension</i> , <b>2017</b> , 35, 1100-1108	1.9 17
195	Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension: a meta-analysis. <i>Journal of Hypertension</i> , <b>2017</b> , 35, 1750-1757	1.9 8
194	Renal Denervation Therapy for Drug-Resistant Hypertension: Does It Still Work?. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2017</b> , 19, 39	2.1 5
193	Effects of Intensive BP Control in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2017</b> , 28, 2812-2823	12.7 234
192	Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study. <i>American Journal of Nephrology</i> , <b>2017</b> , 45, 136-145	4.6 10
191	Air pollution and arterial hypertension. A new risk factor is in the air. <i>Journal of the American Society of Hypertension</i> , <b>2017</b> , 11, 709-715	39
190	Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?. <i>Current Vascular Pharmacology</i> , <b>2017</b> , 16, 66-69	3.3 5
189	Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. <i>American Journal of Medicine</i> , <b>2017</b> , 130, 1465.e27-1465.e39	2.4 10
188	Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease: A Secondary Analysis of a Randomized Trial. <i>Annals of Internal Medicine</i> , <b>2017</b> , 167, 375-383	8 54
187	renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention Trial. <i>Kidney International Reports</i> , <b>2017</b> , 2, 713-720	4.1 17

186	Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Intervention Trial). <i>Hypertension</i> , <b>2017</b> , 70, 751-758	8.5	48
185	Reply. <i>Journal of Hypertension</i> , <b>2017</b> , 35, 200	1.9	
184	Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. <i>Diabetes Care</i> , <b>2017</b> ,	14.6	53
183	Renal sympathetic denervation resurrected; or NOT?. <i>Journal of the American Society of Hypertension</i> , <b>2017</b> , 11, 700-703		
182	Time in Therapeutic Range, as a Determinant of All-Cause Mortality in Patients With Hypertension. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	12
181	From Essential Hypertension to intensive blood pressure lowering: the pros and cons of lower target values. <i>European Heart Journal</i> , <b>2017</b> , 38, 3258-3271	9.5	12
180	Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?. <i>Current Vascular Pharmacology</i> , <b>2017</b> , 16, 30-43	3.3	5
179	Effect of Intensive Blood Pressure Lowering on Incident Atrial Fibrillation and P-Wave Indices in the ACCORD Blood Pressure Trial. <i>American Journal of Hypertension</i> , <b>2016</b> , 29, 1276-1282	2.3	22
178	Renal Sympathetic Denervation: Hibernation or Resurrection?. <i>Cardiology</i> , <b>2016</b> , 135, 87-97	1.6	5
177	Catheter-based radio-frequency renal nerve denervation lowers blood pressure in obese hypertensive swine model. <i>Journal of Hypertension</i> , <b>2016</b> , 34, 1854-62	1.9	16
176	Hypertension and Atherosclerosis: Pathophysiology, Mechanisms and Benefits of BP Control <b>2016</b> , 201-216		4
175	Device-Based Therapy for Drug-Resistant Hypertension: An Update. <i>Current Hypertension Reports</i> , <b>2016</b> , 18, 64	4.7	8
174	Cardiovascular Outcomes in Action to Control Cardiovascular Risk in Diabetes: Impact of Blood Pressure Level and Presence of Kidney Disease. <i>American Journal of Nephrology</i> , <b>2016</b> , 43, 271-80	4.6	28
173	Selecting Optimum Antihypertensive Therapy <b>2016</b> , 217-247		
172	Renal Denervation: A Historical Perspective. <i>Updates in Hypertension and Cardiovascular Protection</i> , <b>2016</b> , 201-213	0.1	
171	Renal Fibromuscular Dysplasia: A Not So Common Entity of Secondary Hypertension. <i>Journal of Clinical Hypertension</i> , <b>2016</b> , 18, 240-6	2.3	9
170	Improvement in All-Cause Mortality With Blood Pressure Control in a Group of US Veterans With Drug-Resistant Hypertension. <i>Journal of Clinical Hypertension</i> , <b>2016</b> , 18, 33-9	2.3	10
169	Regarding "Severe bilateral renal artery stenosis after transluminal radiofrequency ablation of renal sympathetic nerve plexus". <i>Journal of Vascular Surgery</i> , <b>2015</b> , 62, 539	3.5	1

168	Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study. <i>Hypertension</i> , <b>2015</b> , 66, 945-53	8.5	19
167	Catheter-based renal denervation for resistant hypertension: Twenty-four month results of the EnligHTN I first-in-human study using a multi-electrode ablation system. <i>International Journal of Cardiology</i> , <b>2015</b> , 201, 345-50	3.2	28
166	Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. <i>Kidney International</i> , <b>2015</b> , 87, 649-59	9.9	124
165	Effects of multielectrode renal denervation on cardiac and neurohumoral adaptations in resistant hypertension with cardiac hypertrophy: an EnligHTN I substudy. <i>Journal of Hypertension</i> , <b>2015</b> , 33, 346-53	1.9	16
164	Drug therapy for the patient with resistant hypertension. <i>Future Cardiology</i> , <b>2015</b> , 11, 191-202	1.3	1
163	Screening for Primary Aldosteronism: Whom and How?. <i>Journal of Clinical Hypertension</i> , <b>2015</b> , 17, 547-8	2.3	6
162	Impact of multi-electrode renal sympathetic denervation on short-term blood pressure variability in patients with drug-resistant hypertension. Insights from the EnligHTN I study. <i>International Journal of Cardiology</i> , <b>2015</b> , 180, 237-42	3.2	13
161	Sympathetic Renal Denervation Using the EnligHTN Multi-electrode Ablation System: The St Jude Experience <b>2015</b> , 69-79		
160	Renal denervation and Symplicity HTN-3: "Dubium sapientiae initium" (doubt is the beginning of wisdom). <i>Circulation Research</i> , <b>2014</b> , 115, 211-4	15.7	39
159	Electrical stimulation of the renal arterial nerves does not unmask the blindness of renal denervation procedure in swine. <i>International Journal of Cardiology</i> , <b>2014</b> , 176, 1061-3	3.2	9
158	Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system. <i>Hypertension</i> , <b>2014</b> , 64, 565-72	8.5	55
157	Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. <i>Diabetes Care</i> , <b>2014</b> , 37, 686-93	14.6	17
156	Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 1217-22	3	99
155	Renal nerve ablation for resistant hypertension: how did we get here, present status, and future directions. <i>Circulation</i> , <b>2014</b> , 129, 1440-51	16.7	40
154	Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. <i>Journal of Hypertension</i> , <b>2014</b> , 32, 415-22	1.9	59
153	Renal and cardiac effects of renal sympathetic denervation and carotid baroreceptor stimulation. <i>Current Vascular Pharmacology</i> , <b>2014</b> , 12, 55-62	3.3	10
152	Non-interventional management of resistant hypertension. <i>World Journal of Cardiology</i> , <b>2014</b> , 6, 1080-90	0.1	4
151	Renal nerve ablation for resistant hypertension: the dust has not yet settled. <i>Journal of Clinical Hypertension</i> , <b>2014</b> , 16, 399-400	2.3	3

150	Apelin and relaxin plasma levels in young healthy offspring of patients with essential hypertension. <i>Journal of Clinical Hypertension</i> , <b>2014</b> , 16, 198-201	2.3	6
149	Response to letter to the editor: "Renal artery stenosis may be responsible for the gradual return of high blood pressure after renal denervation". <i>Journal of Clinical Hypertension</i> , <b>2014</b> , 16, 314	2.3	
148	Statin therapy, fitness, and mortality risk in middle-aged hypertensive male veterans. <i>American Journal of Hypertension</i> , <b>2014</b> , 27, 422-30	2.3	19
147	Unintentional overestimation of an expected antihypertensive effect in drug and device trials: mechanisms and solutions. <i>International Journal of Cardiology</i> , <b>2014</b> , 172, 29-35	3.2	28
146	Halting arterial aging in patients with cardiovascular disease: hypolipidemic and antihypertensive therapy. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 6339-49	3.3	14
145	Gender differences in hypertension: myths and reality. <i>Current Hypertension Reports</i> , <b>2013</b> , 15, 321-30	4.7	86
144	Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. <i>European Heart Journal</i> , <b>2013</b> , 34, 2132-40	9.5	230
143	Catheter-based renal sympathetic denervation exerts acute and chronic effects on renal hemodynamics in swine. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 987-92	3.2	34
142	Albuminuria and cognitive decline in people with diabetes and normal renal function. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2013</b> , 8, 1907-14	6.9	34
141	Impressive blood pressure and heart rate response after percutaneous renal denervation in a woman with morbid obesity and severe drug-resistant hypertension. <i>Journal of Clinical Hypertension</i> , <b>2013</b> , 15, 852-5	2.3	6
140	Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels. <i>Journal of Clinical Hypertension</i> , <b>2013</b> , 15, 333-6	2.3	32
139	Effects of continuous positive airway pressure on blood pressure in hypertensive patients with obstructive sleep apnea: a 3-year follow-up. <i>Journal of Hypertension</i> , <b>2013</b> , 31, 352-60	1.9	27
138	Exercise capacity and progression from prehypertension to hypertension. <i>Hypertension</i> , <b>2012</b> , 60, 333-8	8.5	83
137	Relation of impaired coronary microcirculation to increased urine albumin excretion in patients with systemic hypertension and no epicardial coronary arterial narrowing. <i>American Journal of Cardiology</i> , <b>2012</b> , 109, 1026-30	3	10
136	Baroreflex activation therapy and resistant hypertension randomization is not enough, you should measure blood pressure appropriately. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 541; author reply 541-2	15.1	1
135	Carotid baroreceptor activation for the treatment of resistant hypertension and heart failure. <i>Current Hypertension Reports</i> , <b>2012</b> , 14, 238-46	4.7	21
134	Body mass index, exercise capacity, and mortality risk in male veterans with hypertension. <i>American Journal of Hypertension</i> , <b>2012</b> , 25, 444-50	2.3	31
133	Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. <i>Hypertension</i> , <b>2012</b> , 59, 926-33	8.5	66

132	Achieving renal denervation: catheter-based and surgical management for neural ablation in the management of hypertension. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , <b>2012</b> , 7, 314-22	1.5	
131	Heart rate recovery, exercise capacity, and mortality risk in male veterans. <i>European Journal of Preventive Cardiology</i> , <b>2012</b> , 19, 177-84	3.9	21
130	Physicians' perceptions and adherence to guidelines for the management of hypertension: a national, multicentre, prospective study. <i>International Journal of Hypertension</i> , <b>2012</b> , 2012, 503821	2.4	21
129	Blood pressure control among US veterans: a large multiyear analysis of blood pressure data from the Veterans Administration health data repository. <i>Circulation</i> , <b>2012</b> , 125, 2462-8	16.7	64
128	Achieving Renal Denervation: Catheter-Based and Surgical Management for Neural Ablation in the Management of Hypertension. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , <b>2012</b> , 7, 314-322	1.5	
127	Carotid baroreceptor stimulation for the treatment of resistant hypertension. <i>International Journal of Hypertension</i> , <b>2011</b> , 2011, 964394	2.4	19
126	Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension. <i>International Journal of Hypertension</i> , <b>2011</b> , 2011, 196518	2.4	22
125	Pathophysiology of resistant hypertension: the role of sympathetic nervous system. <i>International Journal of Hypertension</i> , <b>2011</b> , 2011, 642416	2.4	83
124	Difficult-to-Treat or Resistant Hypertension: Etiology, Pathophysiology, and Innovative Therapies. <i>International Journal of Hypertension</i> , <b>2011</b> , 2011, 438198	2.4	3
123	Common secondary causes of resistant hypertension and rational for treatment. <i>International Journal of Hypertension</i> , <b>2011</b> , 2011, 236239	2.4	49
122	Renal sympathetic denervation in hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2011</b> , 20, 647-53	3.5	22
121	Left ventricular hypertrophy: not so much determinant of renal outcome?. <i>Journal of Hypertension</i> , <b>2011</b> , 29, 622	1.9	
120	Implantation of a carotid baroreceptor stimulator in patients with pacemakers and hypertension. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>2011</b> , 34, 354-6	1.6	7
119	Relationships of osteoprotegerin with albuminuria and asymmetric dimethylarginine in essential hypertension: integrating vascular dysfunction. <i>Expert Opinion on Therapeutic Targets</i> , <b>2011</b> , 15, 1347-53	6.4	4
118	Renal denervation for sleep apnea and resistant hypertension: alternative or complementary to effective continuous positive airway pressure treatment?. <i>Hypertension</i> , <b>2011</b> , 58, e191; author reply e192	8.5	3
117	Benefits from treatment and control of patients with resistant hypertension. <i>International Journal of Hypertension</i> , <b>2010</b> , 2011, 318549	2.4	12
116	Hypertrophic and hypertensive hypertrophic cardiomyopathy--a true association?. <i>Angiology</i> , <b>2010</b> , 61, 92-9	2.1	5
115	Exercise capacity and mortality in older men: a 20-year follow-up study. <i>Circulation</i> , <b>2010</b> , 122, 790-7	16.7	230



114	Hypertension crisis. <i>Blood Pressure</i> , <b>2010</b> , 19, 328-36	1.7	56
113	Relationship of ambulatory arterial stiffness index with blood pressure response to exercise in the early stages of hypertension. <i>Blood Pressure Monitoring</i> , <b>2010</b> , 15, 132-8	1.3	17
112	Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk. <i>Journal of Hypertension</i> , <b>2010</b> , 28, 2299-308	1.9	37
111	In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study. <i>Journal of Hypertension</i> , <b>2010</b> , 28, 1541-6	1.9	33
110	ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: a cross-sectional study. <i>American Journal of Kidney Diseases</i> , <b>2010</b> , 55, 1050-9	7.4	51
109	Renal sympathetic denervation and systemic hypertension. <i>American Journal of Cardiology</i> , <b>2010</b> , 105, 570-6	3	61
108	Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study). <i>American Journal of Cardiology</i> , <b>2010</b> , 106, 999-1005	3	31
107	Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease. <i>Journal of the American College of Surgeons</i> , <b>2010</b> , 211, 384-90	4.4	63
106	A graded association of exercise capacity and all-cause mortality in males with high-normal blood pressure. <i>Blood Pressure</i> , <b>2009</b> , 18, 261-7	1.7	33
105	Telmisartan for prevention of cardiovascular events. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 302; author reply 303	59.2	2
104	A graded association of exercise capacity and all-cause mortality in males with high-normal blood pressure. <i>Blood Pressure</i> , <b>2009</b> , 18, 261-267	1.7	2
103	Low-dose fixed combination of bisoprolol/hydrochlorothiazide as first line for hypertension: a review of the rationale and clinical evidence. <i>Angiology</i> , <b>2009</b> , 60, 601-7	2.1	4
102	Protective effects of angiotensin-converting enzyme inhibitors in high-risk African American men with coronary heart disease. <i>Journal of Clinical Hypertension</i> , <b>2009</b> , 11, 621-6	2.3	2
101	Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension. <i>American Journal of Cardiology</i> , <b>2009</b> , 103, 273-8	3	16
100	Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events. <i>American Heart Journal</i> , <b>2009</b> , 157, S24-30	4.9	14
99	Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction. <i>American Heart Journal</i> , <b>2009</b> , 157, S17-23	4.9	16
98	Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , <b>2009</b> , 16, 242-8		20
97	Metoprolol succinate combination in the treatment of hypertension. <i>Angiology</i> , <b>2009</b> , 60, 608-13	2.1	8

96	Treatment strategies to prevent stroke: focus on optimal lipid and blood pressure control. <i>Expert Opinion on Pharmacotherapy</i> , <b>2009</b> , 10, 955-66	4	3
95	Carotid baroreceptor stimulation as a therapeutic target in hypertension and other cardiovascular conditions. <i>Expert Opinion on Therapeutic Targets</i> , <b>2009</b> , 13, 413-25	6.4	26
94	On target to dual block RAS?. <i>Angiology</i> , <b>2009</b> , 60, 739-49	2.1	1
93	Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study). <i>Blood Pressure</i> , <b>2009</b> , 18, 180-6	1.7	9
92	Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study. <i>Journal of Hypertension</i> , <b>2009</b> , 27, 744-52	1.9	47
91	National utilization of antihypertensive medications from 2000 to 2006 in the Veterans Health Administration: focus on thiazide diuretics. <i>Journal of Clinical Hypertension</i> , <b>2008</b> , 10, 770-8	2.3	10
90	Evaluation and treatment of resistant or difficult-to-control hypertension. <i>Journal of Clinical Hypertension</i> , <b>2008</b> , 10, 837-43	2.3	11
89	Exercise capacity and mortality in black and white men. <i>Circulation</i> , <b>2008</b> , 117, 614-22	16.7	296
88	Beta-blockers in the management of hypertension: focus on nebivolol. <i>Expert Review of Cardiovascular Therapy</i> , <b>2008</b> , 6, 471-9	2.5	21
87	Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study. <i>American Journal of Hypertension</i> , <b>2008</b> , 21, 701-7	2.3	5
86	Aggressive blood pressure control and stroke prevention: role of calcium channel blockers. <i>Journal of Hypertension</i> , <b>2008</b> , 26, 844-52	1.9	17
85	Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study. <i>Journal of Hypertension</i> , <b>2008</b> , 26, 1472-6	1.9	13
84	Does rapidity of blood pressure lowering affect outcomes in hypertension treatment?. <i>Current Cardiovascular Risk Reports</i> , <b>2008</b> , 2, 255-261	0.9	1
83	Exceptional early blood pressure control rates: the ACCOMPLISH trial. <i>Blood Pressure</i> , <b>2007</b> , 16, 80-6	1.7	97
82	Electrocardiographic and echocardiographic detection of myocardial infarction in patients with left-ventricular hypertrophy. The LIFE Study. <i>American Journal of Hypertension</i> , <b>2007</b> , 20, 771-6	2.3	3
81	Metabolic side effects and cardiovascular events of diuretics: should a diuretic remain the first choice therapy in hypertension treatment? The case of yes. <i>Clinical and Experimental Hypertension</i> , <b>2007</b> , 29, 503-16	2.2	6
80	Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study. <i>Hypertension</i> , <b>2006</b> , 47, 868-73	8.5	9
79	Resistant hypertension: diagnosis and management. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2006</b> , 11, 113-8	2.6	24

78	Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <i>Circulation</i> , <b>2006</b> , 113, 2201-10	16.7	114
77	Targeting angiotensin II type I receptors to reduce the risk of stroke in patients with hypertension. <i>Expert Opinion on Therapeutic Targets</i> , <b>2006</b> , 10, 231-7	6.4	4
76	Factorial antihypertensive study of an extended-release metoprolol and hydrochlorothiazide combination. <i>American Journal of Hypertension</i> , <b>2006</b> , 19, 1217-25	2.3	15
75	Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy. <i>Hypertension</i> , <b>2005</b> , 46, 492-9	8.5	25
74	Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. <i>American Journal of Hypertension</i> , <b>2005</b> , 18, 3-12	2.3	29
73	Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy (the LIFE Study). <i>American Journal of Cardiology</i> , <b>2005</b> , 95, 280-3	3	6
72	Eulogy for Edward D. Freis, MD*. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 311-312	3	1
71	Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 946-51	3	107
70	Aspirin under fire: aspirin use in the primary prevention of coronary heart disease. <i>Pharmacotherapy</i> , <b>2005</b> , 25, 847-61	5.8	4
69	The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients. <i>Blood Pressure</i> , <b>2005</b> , 14, 31-7	1.7	64
68	Losartan in cardiovascular disease. <i>Future Cardiology</i> , <b>2005</b> , 1, 433-46	1.3	3
67	Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 293, 1595-608	27.4	294
66	Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. <i>Circulation</i> , <b>2004</b> , 110, 1456-62	16.7	379
65	Prognostic significance of left ventricular mass change during treatment of hypertension. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 292, 2350-6	27.4	592
64	Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. <i>Headache</i> , <b>2004</b> , 44, 414-25	4.2	274
63	Cardiovascular risk assessment and triptans. <i>Headache</i> , <b>2004</b> , 44 Suppl 1, S31-9	4.2	20
62	Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). <i>American Journal of Cardiology</i> , <b>2004</b> , 94, 1076-80	3	21
61	Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 44, 1175-80	15.1	61

60	Candesartan cilexetil in cardiovascular disease. <i>Expert Review of Cardiovascular Therapy</i> , <b>2004</b> , 2, 829-35	2.5	10
59	Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. <i>American Heart Journal</i> , <b>2004</b> , 148, 538-44	4.9	21
58	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in African-American patients with hypertension. <i>Journal of Clinical Hypertension</i> , <b>2004</b> , 6, 310-4	2.3	14
57	From hypertension to heart failure. <i>Journal of Clinical Hypertension</i> , <b>2004</b> , 6, 14-7	2.3	9
56	Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: The study on cognition and prognosis in the elderly (SCOPE). <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 44, 1175-1180	15.1	135
55	Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study. <i>Journal of Hypertension</i> , <b>2003</b> , 21, 781-7	1.9	65
54	Comparative prognostic value of systolic, diastolic, and pulse pressure. <i>American Journal of Cardiology</i> , <b>2003</b> , 91, 433-5	3	6
53	Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study. <i>American Heart Journal</i> , <b>2003</b> , 145, 919-25	4.9	30
52	Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment. <i>American Journal of Hypertension</i> , <b>2003</b> , 16, 180-6	2.3	8
51	Echocardiographic wall motion abnormalities in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. <i>Hypertension</i> , <b>2003</b> , 41, 75-82	8.5	33
50	Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). <i>American Journal of Cardiology</i> , <b>2002</b> , 89, 337-41	3	53
49	Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). <i>American Journal of Cardiology</i> , <b>2002</b> , 89, 399-402	3	14
48	Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. <i>Circulation</i> , <b>2002</b> , 106, 227-32	16.7	70
47	Analysis of T-wave morphology from the 12-lead electrocardiogram for prediction of long-term prognosis in male US veterans. <i>Circulation</i> , <b>2002</b> , 105, 1066-70	16.7	130
46	Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. <i>Circulation</i> , <b>2002</b> , 105, 1071-6	16.7	154
45	Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. <i>Journal of Hypertension</i> , <b>2002</b> , 20, 1445-50	1.9	63
44	Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. <i>Journal of Hypertension</i> , <b>2002</b> , 20, 405-12	1.9	123
43	Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). <i>Journal of Clinical Hypertension</i> , <b>2002</b> , 4, 393-404	2.3	720

42	Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. <i>American Heart Journal</i> , <b>2002</b> , 143, 319-26	4.9	107
41	Regression of hypertensive left ventricular hypertrophy by angiotensin receptor blockade versus beta-blockade: the LIFE trial. <i>American Journal of Hypertension</i> , <b>2002</b> , 15, A15	2.3	3
40	Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <i>Hypertension</i> , <b>2001</b> , 37, 19-27	8.5	87
39	Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2001</b> , 285, 1585-91	27.4	708
38	Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. <i>Blood Pressure</i> , <b>2001</b> , 10, 74-82	1.7	97
37	Effects of mental stress on coronary epicardial vasomotion and flow velocity in coronary artery disease: relationship with hemodynamic stress responses. <i>Journal of the American College of Cardiology</i> , <b>2001</b> , 37, 1359-66	15.1	85
36	Exercise as hypertension therapy. <i>Cardiology Clinics</i> , <b>2001</b> , 19, 507-16	2.5	67
35	Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction. <i>Journal of Hypertension</i> , <b>2001</b> , 19, 1883-91	1.9	86
34	Exercise and hypertension. <i>Coronary Artery Disease</i> , <b>2000</b> , 11, 99-102	1.4	44
33	Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension. <i>Journal of Hypertension</i> , <b>2000</b> , 18, 1129-38	1.9	60
32	Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint. <i>American Journal of Cardiology</i> , <b>2000</b> , 85, 466-72	3	140
31	Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population : the LIFE study. <i>Hypertension</i> , <b>2000</b> , 35, 6-12	8.5	200
30	Chronic heart failure and exercise. <i>American Heart Journal</i> , <b>2000</b> , 140, 21-8	4.9	32
29	Effects of moderate intensity exercise on serum lipids in African-American men with severe systemic hypertension. <i>American Journal of Cardiology</i> , <b>1998</b> , 81, 732-5	3	28
28	Efficacy of low-dose combination of bisoprolol/hydrochlorothiazide compared with amlodipine and enalapril in men and women with essential hypertension. <i>American Journal of Cardiology</i> , <b>1998</b> , 81, 1363-5	3	7
27	Influence of risk factors on peripheral and cerebrovascular disease in men with coronary artery disease, low high-density lipoprotein cholesterol levels, and desirable low-density lipoprotein cholesterol levels. HIT Investigators. Department of Veterans Affairs HDL Intervention Trial. <i>American Journal of Cardiology</i> , <b>1998</b> , 81, 734-40	4.9	24
26	Low-dose combination treatment for hypertension versus single-drug treatment-bisoprolol/hydrochlorothiazide versus amlodipine, enalapril, and placebo: combined analysis of comparative studies. <i>American Journal of Therapeutics</i> , <b>1998</b> , 5, 313-21	1	11
25	Tolerability profile of tasosartan, a long-acting angiotensin II AT1 receptor blocker, in the treatment of patients with essential hypertension. <i>Current Therapeutic Research</i> , <b>1997</b> , 58, 930-943	2.4	1

24	Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group. <i>Journal of the American College of Cardiology</i> , <b>1997</b> , 30, 1802-8	15.1	28
23	Effects of aerobic training on exaggerated blood pressure response to exercise in African-Americans with severe systemic hypertension treated with indapamide +/- verapamil +/- enalapril. <i>American Journal of Cardiology</i> , <b>1997</b> , 79, 1424-6	3	34
22	Transient coronary occlusion with mental stress. <i>American Heart Journal</i> , <b>1996</b> , 132, 1299-301	4.9	20
21	The role of exercise in the control of hypertension and cardiovascular risk. <i>Current Opinion in Nephrology and Hypertension</i> , <b>1996</b> , 5, B153	3.5	7
20	Regional cardiac compression due to a large anaerobic bacterial empyema. <i>Clinical Cardiology</i> , <b>1996</b> , 19, 332-4	3.3	
19	Effect of hydrochlorothiazide therapy on cardiac arrhythmias in African-American men with systemic hypertension and moderate to severe left ventricular hypertrophy. <i>American Journal of Cardiology</i> , <b>1996</b> , 78, 886-9	3	7
18	Electrocardiographic abnormalities suggestive of myocardial ischemia during upper gastrointestinal bleeding. <i>American Journal of Cardiology</i> , <b>1995</b> , 75, 312-4	3	12
17	Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 1462-7	59.2	234
16	Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. <i>American Heart Journal</i> , <b>1995</b> , 130, 359-66	4.9	68
15	Cardiorespiratory fitness and coronary heart disease risk factor association in women. <i>Journal of the American College of Cardiology</i> , <b>1995</b> , 26, 358-64	15.1	40
14	Effects of diltiazem, metoprolol, enalapril and hydrochlorothiazide on frequency of ventricular premature complexes. <i>American Journal of Cardiology</i> , <b>1994</b> , 73, 242-6	3	6
13	Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. <i>American Journal of Medicine</i> , <b>1993</b> , 94, 181-7	2.4	69
12	Diuretics, potassium, and ventricular arrhythmias. <i>JAMA - Journal of the American Medical Association</i> , <b>1992</b> , 268, 52-3	27.4	
11	Therapeutic adherence in the elderly: transdermal clonidine compared to oral verapamil for hypertension. <i>American Journal of Medicine</i> , <b>1991</b> , 91, 22S-28S	2.4	27
10	Effects of diuretic therapy and exercise-related arrhythmias in systemic hypertension. <i>American Journal of Cardiology</i> , <b>1989</b> , 64, 1152-6	3	11
9	Exercise blood pressure response and left ventricular hypertrophy. <i>American Journal of Hypertension</i> , <b>1989</b> , 2, 114-6	2.3	32
8	Thiazide Therapy Is Not a Cause of Arrhythmia in Patients With Systemic Hypertension. <i>Archives of Internal Medicine</i> , <b>1988</b> , 148, 1272		44
7	Diuretics, hypokalemia, and cardiac arrhythmias: a critical analysis. <i>American Heart Journal</i> , <b>1986</b> , 111, 1217-24	4.9	40

6	Effectiveness of Potassium Chloride or Triamterene in Thiazide Hypokalemia. <i>Archives of Internal Medicine</i> , <b>1985</b> , 145, 1986		8
5	How dangerous are diuretics?. <i>Drugs</i> , <b>1985</b> , 30, 469-74	12.1	13
4	Effect of diuretic therapy on ventricular arrhythmias in hypertensive patients with or without left ventricular hypertrophy. <i>American Heart Journal</i> , <b>1985</b> , 110, 595-9	4.9	38
3	Echocardiographic assessment by computer-assisted analysis of diastolic left ventricular function and hypertrophy in borderline or mild systemic hypertension. <i>American Journal of Cardiology</i> , <b>1985</b> , 56, 546-50	3	62
2	Early changes in plasma and urinary potassium in diuretic-treated patients with systemic hypertension. <i>American Journal of Cardiology</i> , <b>1984</b> , 54, 1015-9	3	16
1	Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias. <i>American Journal of Cardiology</i> , <b>1983</b> , 52, 1017-22	3	98